This post was originally published on this site Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. The data was presented April 1–2 at this year’s American Association for Cancer Research Annual Meeting, held in…
This post was originally published on this site The American Lung Association and Foundation for Sarcoidosis Research are working together during April’s Sarcoidosis Awareness Month to offer U.S. sarcoidosis patients and caregivers additional support, making available in-person support groups and online tutorials by specialists. As part of the activities of Sarcoidosis Awareness Month, the associations…
This post was originally published on this site The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and efficacy, has been reviewed and approved by regulatory authorities in Poland, where the study will be conducted.…
This post was originally published on this site A Phase 1/2 clinical trial testing a triple immunotherapy combination for newly diagnosed glioblastoma has completed patient enrollment three months ahead of schedule. Inovio Pharmaceuticals, the company leading the trial, announced the trial (NCT03491683) has enrolled the planned 52 participants at centers across the U.S. The trial is…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has expanded the use of Ibrance (palbociclib) capsules in combination with an aromatase inhibitor or Faslodex (fulvestrant) to men with a subset of advanced breast cancer. The approval of Pfizer’s supplemental New Drug Application (sNDA) makes such first-line treatment available for…
This post was originally published on this site France’s OSE Immunotherapeutics and Léon Bérard Cancer Center have established a research collaboration to use analysis based on artificial intelligence (AI) to identify new targets for cancer immunotherapies. Under the collaboration, researchers will analyze tumor biopsies and patient data to identify the molecular players underlying resistance to PD-1/PD-L1…
This post was originally published on this site A Phase 1 trial evaluating Samumed’s investigational compound SM07883 for Alzheimer’s disease has dosed its first participant. The Phase 1 trial (ACTRN12619000327189), taking place in Australia, will assess the safety, tolerability, and pharmacokinetics (the movement of a medicine into, through, and out of the body) of ascending…
This post was originally published on this site Caring for someone with Alzheimer’s disease is much more challenging than most people realize. The stress of taking over a dementia patient’s financial and personal responsibilities, as well as managing their care is exhausting. During the later stages of the disease, patients with dementia need continual help…
This post was originally published on this site The Prostate Cancer Foundation (PCF) has announced the winners of the Scholar-in-Training Awards — research grants to support young scientists who presented outstanding data in the field of prostate cancer. Since 1986, more than 4,580 Scholar-in-Training Awards, encompassing 55 research foundations, corporations, and other organizations dedicated to…
This post was originally published on this site A recent OncLive State of the Science Summit focused on new therapies and other issues in ovarian cancer and soft tissue sarcoma. The March 26 event in New York was chaired by Mario M. Leitao Jr., MD, fellowship director of gynecology service and director of the minimal…
